15 patents
Utility
Methods and Compositions
4 Jan 24
The present invention provides polypeptides capable of targeting antigens, such as neoantigens, to particular immune cells, and associated therapeutic methods.
PETER ELLMARK, PER NORLEN, KARIN HAGERBRAND
Filed: 30 Mar 21
Utility
Novel Peptides
5 Oct 23
The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
Filed: 4 Nov 22
Utility
Novel ANTI-CD137 Antibodies and Uses Thereof
21 Sep 23
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 10 Nov 22
Utility
Novel Polypeptides
10 Mar 22
The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen.
Anna Sall, Peter Ellmark, Adnan Deronic, Fredrika Carlsson, Karin Hagerbrand, Laura Von Schantz
Filed: 17 Dec 19
Utility
Novel Polypeptides
3 Mar 22
The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of targeting a dendritic cell, and a second binding domain, designated B2, which is capable of targeting a tumour cell-associated antigen.
Anna Sall, Peter Ellmark, Adnan Deronic, Fredrika Carlsson, Karin Hagerbrand, Laura Von Schantz
Filed: 17 Dec 19
Utility
Novel Polypeptides
24 Feb 22
The present invention provides bispecific antibodies of an antibody format, and which comprise one or more Fab fragments and an immunoglobulin molecule.
Anna Sall, Laura Von Schantz, Anneli Nilsson, Barnabas Nyesiga, Jessica Petersson, Mattias Levin
Filed: 17 Dec 19
Utility
Combination Therapies with Anti CD40 Antibodies
30 Dec 21
The present invention relates to combination therapies for treating a solid tumour in a subject.
Peter Ellmark, Per Norlen, Niina Veitonmaki
Filed: 15 Sep 21
Utility
Novel Polypeptides
5 Aug 21
The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets.
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
Filed: 13 Apr 21
Utility
Antigen Binding Proteins Binding to 5T4 and 4-1BB and Related Compositions and Methods
15 Jul 20
The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB.
David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
Filed: 19 Jul 18
Utility
Novel Polypeptides
17 Jun 20
The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets.
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
Filed: 2 Feb 20
Utility
Bispecific Antibody Against OX40 and CTLA-4
12 Feb 20
The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to OX40, and a second binding domain capable of specifically binding to CTLA-4.
Peter Ellmark, Christina Furebring, Per Norlen, Niina Veitonmaki
Filed: 30 Apr 18
Utility
Oncofetal Antigen Binding Proteins and Related Compositions and Methods
18 Dec 19
The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB.
David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
Filed: 20 Feb 19
Utility
Novel Anti-CD137 Antibodies and Uses Thereof
20 Nov 19
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 20 Nov 17
Utility
Novel ANTI-CD137 Antibodies and Uses Thereof
20 Nov 19
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 16 Jul 19
Utility
Bispecific Polypeptides to GITR and CTLA-4
9 Oct 19
The present invention provides multispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to GITR, and a second binding domain capable of specifically binding to CTLA-4.
Peter Ellmark, Sara Fritzell, Christina Furebring, Anne Kvarnhammar, Mattias Levin, Per Norlen, Eva Nyblom, Niina Veitonmaki, Magnus Winnerstam
Filed: 20 Nov 17
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first